Literature DB >> 22659521

Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review.

Emmy De Buck1, Nele S Pauwels, Tessa Dieltjens, Veerle Compernolle, Philippe Vandekerckhove.   

Abstract

Hemochromatosis is a disorder of the iron metabolism, characterized by high body iron content, necessitating frequent phlebotomies to remove excess iron. In some countries, this blood is discarded and not used for blood transfusion because of the non-voluntary character of this donation, and because a potential risk of microbial contamination of the donor blood is assumed. A systematic review was performed in order to collect and critically examine solid evidence with regard to the effectiveness and safety of blood for transfusion when derived from hemochromatosis patients who do not suffer from complications or organ damage. Using three databases (The Cochrane Library, MEDLINE, and Embase) we searched for studies from date of inception until January 2012. Out of 3470 articles, 80 references that were relevant to our question were selected, including many opinion pieces, comments, letters, and narrative reviews. Based on our selection criteria, we finally retained only six observational studies, so evidence on this subject is scarce and furthermore, the strength of the available evidence is low to very low, due to poor study designs. We found no evidence that red blood cell concentrates from hemochromatosis patients without complications of iron overload do not comply with the physiological quality requirements for transfusion, nor that their blood would present a greater risk to recipient safety than blood from non-hemochromatosis donors. However, in vitro findings from two studies suggest that iron-overloaded patients would be more susceptible to bacterial growth, but future in vivo studies are warranted to confirm this. Based on this, we call for harmonization of the blood donor selection policy among countries allowing hemochromatosis patients who do not suffer from complications of iron overload to donate blood, once iron levels are normalized.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659521     DOI: 10.1016/j.jhep.2012.04.040

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  1 in total

1.  Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype.

Authors:  Paul Adams; Albert Altes; Pierre Brissot; Barbara Butzeck; Ioav Cabantchik; Rodolfo Cançado; Sonia Distante; Patricia Evans; Robert Evans; Tomas Ganz; Domenico Girelli; Rolf Hultcrantz; Gordon McLaren; Ben Marris; Nils Milman; Elizabeta Nemeth; Peter Nielsen; Brigitte Pineau; Alberto Piperno; Graça Porto; Dianne Prince; John Ryan; Mayka Sanchez; Paulo Santos; Dorine Swinkels; Emerência Teixeira; Ketil Toska; Annick Vanclooster; Desley White
Journal:  Hepatol Int       Date:  2018-03-27       Impact factor: 6.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.